Sierra Oncology, Inc.
NASDAQ: SRRA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Nicholas Glover
- Employees
- 109
- Headquarters
- Vancouver, Canada
- IPO year
- 2015
- Website
- https://www.sierraoncology.com
Loading SRRA…
Loading profile data…Frequently asked questions about SRRA
What does Sierra Oncology, Inc. (SRRA) do?
Sierra Oncology, Inc. is a biopharmaceutical firm focused on the late-stage research, development, and commercialization of therapeutic solutions for patients with blood disorders and various cancers. The company's primary drug candidate is momelotinib, an orally administered, selective inhibitor that targets Janus kinase 1 (JAK1), JAK2, and Act...
Where does SRRA trade?
Sierra Oncology, Inc. (SRRA) trades on the NASDAQ Global Market.
What sector is SRRA in?
Sierra Oncology, Inc. (SRRA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Sierra Oncology, Inc.?
Nicholas Glover is the chief executive officer of Sierra Oncology, Inc. (SRRA).
Where is Sierra Oncology, Inc. headquartered?
Sierra Oncology, Inc. is headquartered in Canada.
Does SRRA pay a dividend?
Sierra Oncology, Inc. (SRRA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SRRA go public?
Sierra Oncology, Inc. (SRRA) completed its initial public offering in 2015.